GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, the Company leverages its integrated development platform by combining a gene therapy-based approach with its core technology platforms of mitochondrial targeting sequence and optogenetics.

GenSight's initial focus has been on developing therapies for severe retinal diseases, with the goal of preserving or restoring vision in patients suffering from sight-threatening ophthalmic diseases.

Paris, FR
Size (employees)
31 (est)
GenSight Biologics was founded in 2011 and is headquartered in Paris, FR
Report incorrect company information

GenSight Biologics Office Locations

GenSight Biologics has an office in Paris
Paris, FR (HQ)
74 Rue du Faubourg Saint-Antoine
Show all (1)
Report incorrect company information

GenSight Biologics Financials and Metrics

GenSight Biologics Financials

Market capitalization (31-Oct-2017)

101.7 m

Closing share price (31-Oct-2017)

GenSight Biologics's current market capitalization is €101.7 m.
Show all financial metrics
Report incorrect company information